Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Ingo Konetzki

Thierry Bouyssou

Andreas Schnapp

Christoph Hoenke

Philipp Lustenberger

Klaus Rudolf

Rainer Walter

Norbert Hauel

Henri Doods

Kurt Schromm

Annette Schuler-Metz

Angelo Ceci

Sabine Pestel

Frank Buettner

Claudia Heine

Hermann Schollenberger

Juergen Mack

Iris Kauffmann-Hefner

Peter Sieger

Marco Santagostino

Dieter Wiedenmayer

Henning Priepke

Michael Paul Pieper

Enzo Cereda

Thomas Trieselmann

Heiner Ebel

Michel Pairet

Riccardo Giovannini

Georg Speck

Richard Reichl

Dieter Wolfgang Hamprecht

Holger Wagner

Rolf Banholzer

Klaus Fuchs

Helmut Meissner

Gerald Pohl

Gerd Morschhaeuser

Matthew Russell Netherton

Bradford S Hamilton

Christopher John Montague Meade

Ruediger Streicher

Daniela Berta

Christopher J Montague Meade

Phillip Lustenberger

The present invention relates to compounds defined by formula I wherein the variables R-Rare defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation

The present invention relates to compounds of general formula I wherein n, R, R, R, R, R, R, Rand Rare defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Bradykinin B1-antagonists

Disclosed are compounds of the formula I wherein A, Y, R, R, R, Rand Rare defined, suitable for treating diseases and symptoms of diseases caused at least to some extent by stimulation of bradykinin-B1 receptors, the preparation thereof and the use thereof.

B1-antagonists

Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumor pain and headache diseases. The following is exemplary: 

Bradykinin B1-receptor antagonists

Novel compounds of which the following is exemplary: 

Compounds

Compounds of the formula I wherein n, R, R, R, R, R, R, R, R, R, R, Rand X are defined as described in the specification, which are bradykinin B1 antagonists, and their use as medicaments.

Compounds as bradykinin B1 antagonists

The present invention relates to compounds of general formula I wherein A, B, D, Y, R, R, R, Rand Rare defined as in the specification, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Aryl sulfonamides as bradykinin-B1-receptor antagonists

A pharmaceutical composition comprising a compound of formula 1 wherein:

Medicaments for the treatment of chronic obstructive pulmonary disease

Enantiomerically pure compounds of general formula 1 wherein the groups R, R, R, R, and Xmay have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments

The present invention relates to new beta-agonists of general formula (I) wherein the groups Rand Rhave the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.

Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups R, R, R, m and Ymay have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly as medicaments for the treatment of respiratory complaints.

Enantiomerically pure beta agonists, manufacturing and use thereof

A compound of formula 1'&#x2033; wherein:

Long acting beta-2-agonists and their use as medicaments

Growing community of inventors

Warthausen, Germany

Ingo Konetzki